B. Riley Securities reiterated coverage on Novavax with a new price target
$NVAX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
B. Riley Securities reiterated coverage of Novavax with a rating of Buy and set a new price target of $37.00 from $74.00 previously